Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time

The large heterogeneity in response to immune checkpoint inhibitors is driving the exploration of predictive biomarkers to identify patients who will respond to such treatment. We extended our previously suggested modeling framework of atezolizumab pharmacokinetics, IL18, and tumor size (TS) dynamic...

Descripción completa

Detalles Bibliográficos
Autores principales: Netterberg, Ida, Bruno, René, Chen, Ya‐Chi, Winter, Helen, Li, Chi‐Chung, Jin, Jin Y., Friberg, Lena E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020300/
https://www.ncbi.nlm.nih.gov/pubmed/31991070
http://dx.doi.org/10.1002/psp4.12489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020300/
https://www.ncbi.nlm.nih.gov/pubmed/31991070
http://dx.doi.org/10.1002/psp4.12489

Ejemplares similares